seewhy
liked
$Citius Pharmaceuticals(CTXR.US$ I forgot to include this in my July 10th BOLO post! But the vote on TENKU merger is coming! As of now the vote is scheduled for 8/2/2024. Also the company has been busy preparing to commercially launch LYMPHIR if the recieve FDA approval! I will post again that PDUFA Date is 8/13/2024!
6
seewhy
commented on
1
2
seewhy
liked
$Sharps Technology(STSS.US$ Its beyond me why they didn’t wait until late today to release the information about the board recommendation for shareholders to vote for the R/S at the meeting on 7/12/24? Why wouldn’t they let this new sale have a full day of trading first? Grrr! Hehehe
3
13
seewhy
liked
Hi, mooers!
In June, following the listings of JPG and OFS, we are thrilled to see three more stocks hitting the market. Eager to know who they are? Follow moomoo to check them out and discover their investment potential!
Who are these 3 new IPO companies?
1.WELL CHIP GROUP BERHAD
Well Chip Group Berhad is a Malaysian company specializing in pawnbroking services, as well as jewelry retail and trading. The group operates 26 outlets in the state of Johor, ...
In June, following the listings of JPG and OFS, we are thrilled to see three more stocks hitting the market. Eager to know who they are? Follow moomoo to check them out and discover their investment potential!
Who are these 3 new IPO companies?
1.WELL CHIP GROUP BERHAD
Well Chip Group Berhad is a Malaysian company specializing in pawnbroking services, as well as jewelry retail and trading. The group operates 26 outlets in the state of Johor, ...
416
252
seewhy
liked
$Innate Pharma(IPHA.US$
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Innate Pharma's Phase 1/2 trial of SAR443579 (SAR’579), developed with Sanofi, continues to show promising results for treating relapsed/refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). The clinical trial results, presented at the European Hematology Association 2024 Congress, hig...
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Innate Pharma's Phase 1/2 trial of SAR443579 (SAR’579), developed with Sanofi, continues to show promising results for treating relapsed/refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). The clinical trial results, presented at the European Hematology Association 2024 Congress, hig...
2
seewhy
liked
$Kaival Brands Innovations(KAVL.US$ But its Friday friends/followers! So that means i have to leave! I will check in if time permits? If not C’ya after market close somewhere this evening! But i would be remiss if i didn’t say that i wish ALL OF YOU A GREAT PROFIT FILLED DAY! 🤝💵
8
5